Forbes June 10, 2024
Bruce Japsen

Abbott Laboratories Monday said the U.S. Food and Drug Administration has cleared for sale two new over-the-counter continuous glucose monitoring systems, devices that could bring more access to millions of people with diabetes.

Abbott said its Lingo device is designed for general consumers who are looking to improve their overall health and wellness while the other device cleared by the FDA known as Rio is for adults with Type-2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications. There are more than 38 million Americans with diabetes in the U.S. alone.

“There is no one-size-fits all approach for glucose monitoring, which is why we’ve designed different products for different people – all based on the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Digital Health, FDA, Govt Agencies, Medical Devices, Technology, Wearables
UN warns of military brain control
Only 20% of AI devices for children used pediatric data to train: 3 notes
Medtech firms have cut thousands of jobs this year. Will layoffs continue in 2025?
Proton therapy market in the US projected to reach $2.67 billion by 2033
How Trump’s second term will affect the medtech industry

Share This Article